Jeffrey A. Bluestone's most recent trade in Gilead Sciences, Inc. was a trade of 4,665 Non-qualified Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Aug. 20, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2026 | 4,665 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Sale of securities on an exchange or to another person at price $ 144.92 per share. | 20 Aug 2026 | 1,816 | 10,066 (0%) | 0% | 144.9 | 263,183 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.45 per share. | 20 Aug 2026 | 1,816 | 11,882 (0%) | 0% | 67.4 | 122,489 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Sale of securities on an exchange or to another person at price $ 145.73 per share. | 20 Aug 2026 | 1,658 | 10,066 (0%) | 0% | 145.7 | 241,618 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.45 per share. | 20 Aug 2026 | 1,658 | 11,724 (0%) | 0% | 67.4 | 111,832 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.45 per share. | 20 Aug 2026 | 1,165 | 11,231 (0%) | 0% | 67.4 | 78,579 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Sale of securities on an exchange or to another person at price $ 143.75 per share. | 20 Aug 2026 | 1,165 | 10,066 (0%) | 0% | 143.8 | 167,474 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2026 | 335 | 11,395 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Sale of securities on an exchange or to another person at price $ 146.26 per share. | 20 Aug 2026 | 335 | 10,066 (0%) | 0% | 146.3 | 48,997 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.35 per share. | 20 Aug 2026 | 335 | 10,401 (0%) | 0% | 61.3 | 20,552 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Sale of securities on an exchange or to another person at price $ 146.35 per share. | 20 Aug 2026 | 26 | 10,066 (0%) | 0% | 146.3 | 3,805 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.46 per share. | 20 Aug 2026 | 26 | 10,092 (0%) | 0% | 67.5 | 1,754 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2026 | 4,884 | 4,884 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2026 | 1,146 | 10,066 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.45 per share. | 20 Jan 2026 | 5,000 | 13,920 (0%) | 0% | 67.5 | 337,250 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 5,000 | 4,665 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Sale of securities on an exchange or to another person at price $ 123.50 per share. | 20 Jan 2026 | 5,000 | 8,920 (0%) | 0% | 123.5 | 617,500 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 64.92 per share. | 28 Nov 2025 | 5,000 | 13,920 (0%) | 0% | 64.9 | 324,600 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2025 | 5,000 | 7,648 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Sale of securities on an exchange or to another person at price $ 125.08 per share. | 28 Nov 2025 | 5,000 | 8,920 (0%) | 0% | 125.1 | 625,400 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.45 per share. | 14 Jul 2025 | 5,000 | 13,920 (0%) | 0% | 67.5 | 337,250 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jul 2025 | 5,000 | 9,665 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Sale of securities on an exchange or to another person at price $ 109.74 per share. | 14 Jul 2025 | 5,000 | 8,920 (0%) | 0% | 109.7 | 548,700 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2025 | 6,809 | 6,809 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2025 | 1,516 | 5,713 | - | - | Restricted Stock Unit | |
| Gilead Sciences | A. Bluestone Jeffrey | Director | Sale of securities on an exchange or to another person at price $ 91.39 per share. | 26 Nov 2024 | 6,788 | 8,920 (0%) | 0% | 91.4 | 620,356 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Nov 2024 | 5,879 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jeffrey Bluestone A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.17 per share. | 26 Nov 2024 | 5,879 | 11,587 (0%) | 0% | 61.2 | 359,618 | Common Stock |
| Gilead Sciences | Bluestone A. Jeffrey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Nov 2024 | 4,121 | 11,730 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | A. Bluestone Jeffrey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.35 per share. | 26 Nov 2024 | 4,121 | 15,708 (0%) | 0% | 61.3 | 252,823 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 12,648 | 12,648 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 2,310 | 4,197 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 10,173 | 10,173 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 1,887 | 1,887 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 15,851 | 15,851 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 2,444 | 5,708 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 2,223 | 0 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 2,223 | 3,264 (0%) | 0% | - | Common Stock |